Gilead Sciences, Inc. (GILD) Announces Phase 1 Data For Investigational Therapy, GS-6615, In Patients With Long QT-3 Syndrome
5/12/2014 9:19:30 AM
SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1 clinical trial (GS-US-279-0110) of GS-6615, an investigational, selective late sodium current inhibitor, showing a shortening of the QTc interval (the time interval between the start of the Q-wave and end of the T-wave in the heart’s electrical cycle) in patients with long QT-3 (LQT3) syndrome. LQT3 is a genetic disorder that prolongs the heart’s QTc interval and can cause life-threatening cardiac arrhythmias (abnormal heartbeats). Results from this study (Abstract #AB34-05) will be presented today in San Francisco at the annual meeting of the Heart Rhythm Society.
Help employers find you! Check out all the jobs and post your resume.
comments powered by